CERE 120

Drug Profile

CERE 120

Alternative Names: AAV-NRTN; AAV-NTN; AAV2-neurturin; AAV2-NTN; CERE-120; Neurturin gene therapy

Latest Information Update: 11 Jan 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Ceregene
  • Developer Sangamo BioSciences
  • Class Antiparkinsonians; Gene therapies
  • Mechanism of Action Nerve tissue protein modulators; Neurturin agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Discontinued Eye disorders; Huntington's disease; Parkinson's disease

Most Recent Events

  • 06 Jan 2017 Sangamo Biosciences is now called Sangamo Therapeutics
  • 01 Mar 2015 Discontinued - Phase-II for Parkinson's disease in United Kingdom (Intrastriatal)
  • 01 Mar 2015 Discontinued - Phase-II for Parkinson's disease in USA (Intrastriatal)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top